Enovis Corporation · NYSE:ENOV

Enovis — Q1 2025 Earnings Presentation

17 slides from Enovis's earnings presentation, May 8, 2025

  1. Slide 1: First Quarter 2025 Results

    First Quarter 2025 Results May 8, 2025

  2. Slide 2: Forward-looking Statements Non-GAAP Financial Information

    Forward-looking Statements Non-GAAP Financial Information This presentation includes forward-looking statements, including forward-looking statements Enovis has provided in this presentation financial information that has not been prepared in accordance with within the meaning of the U.S. Private Se

  3. Slide 3: Q1 2025 Highlights

    Q1 2025 Highlights • +8% reported growth, +10% xFx on a comparable basis • +13% comparable growth in Recon • +8% comparable growth in P&R • Q1 results include a ~350bps tailwind from additional selling days • Momentum building for new product launches • Recent launches driving share gains, more comi

  4. Slide 4: Q1 Reconstructive Segment Sales Performance

    Q1 Reconstructive Segment Sales Performance Reconstructive Q1 Sales • WW performance back to above market growth • +13% Recon growth on a comparable basis Growth*: +11% Y/Y, +13% comparable • DD global growth in both Hip/Knee and Extremities • US comparable growth of 11% • US channel integration com

  5. Slide 5: Q1 Prevention & Recovery Segment Sales Performance

    Q1 Prevention & Recovery Segment Sales Performance P&R Q1 Sales • Comparable growth of 8% Growth*: +5% Y/Y, +8% Comparable • Global Bracing growth of 9% • Adjusted EBITDA margin expansion +50bps • EGX initiatives driving positive mix and underlying productivity Recovery Sciences Q1 ‘25 • Growing mom

  6. Slide 6: P&L Performance

    P&L Performance • +8% sales growth as reported, +10% comparable millions Q1 2024 Q1 2025 constant currency Net Sales $516 $559 • Adjusted gross margin expansion of +300bps driven Adj. Gross Profit by product mix and EGX efficiency improvements $303 $345 Margin 58.7% 61.7% • Continued investments in

  7. Slide 7: Full Year 2025 Outlook

    Full Year 2025 Outlook February May Comments • Global markets grow in line with historical Revenue $2.19-$2.22B $2.22-$2.25B averages • ~6.0-6.5% core organic xFx growth aEBITDA $405-$415mm $385-$395mm • HSD recon growth, P&R stable at LSD • Fx = Flat vs. PY at current rates Depreciation $125-$130mm

  8. Slide 8: Implementing Actions to Mitigate Tariff Exposure

    Implementing Actions to Mitigate Tariff Exposure Tariff Exposure Comments • Largely optimized manufacturing footprint in-region for region ~$40m • >90% of exposure is in P&R, with majority on China-sourced products; impact realized in H2 2025 Exposure 100% • Multi-year, EGX-driven, optimization prog

  9. Slide 9: Summary

    Summary • Strong start to 2025 and underlying fundamentals across key businesses • Above market Recon growth and new product launches in position to accelerate commercial momentum • Proactively managing dynamic global trade environment © 2025 Enovis Corporation 9

  10. Slide 10: Appendix

    Appendix enovis. Creating Better Together” 10

  11. Slide 11: QTD Comparable Sales

    QTD Comparable Sales © 2025 Enovis Corporation

  12. Slide 12: QTD Adjusted EPS Reconciliation

    QTD Adjusted EPS Reconciliation © 2025 Enovis Corporation

  13. Slide 13: QTD Adjusted EBITDA Reconciliation

    QTD Adjusted EBITDA Reconciliation © 2025 Enovis Corporation

  14. Slide 14: QTD Adjusted Gross Margin Reconciliation

    QTD Adjusted Gross Margin Reconciliation © 2025 Enovis Corporation

  15. Slide 15: Q1'25 GAAP to Adjusted Non-GAAP Financial Measures

    Q1’25 GAAP to Adjusted Non-GAAP Financial Measures © 2025 Enovis Corporation

  16. Slide 16: Q1'24 GAAP to Adjusted Non-GAAP Financial Measures

    Q1’24 GAAP to Adjusted Non-GAAP Financial Measures © 2025 Enovis Corporation

  17. Slide 17: enovis. Creating Better Together

    enovis. Creating Better Together”

Enovis — Q1 2025 Earnings Presentation on 6ix